Werewolf Therapeutics Q3 net loss $8.3M; WTX-124 shows early antitumor activity

Werewolf Therapeutics, Inc.

2023-Q3 EPS reported -$0.72

Cash $130.1M as of Sep 30; sufficient to fund operations through Q4 2024.
Collaboration revenue $5.9M (vs $5.0M prior year); net loss $8.3M (vs $11.9M).
WTX-124 Phase 1 data: well-tolerated, two unconfirmed partial responses at 12 mg, no Grade 3+ related AEs.
WTX-330 dose escalation ongoing; WTX-124 expansion expected to open in H1 2024.
New pipeline candidate WTX-518 (IL-18 INDUKINE) added; preclinical data in H1 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Werewolf Therapeutics, Inc. reported the third quarter ended September 30, 2023 results: revenue $5.9 million.

Period: the third quarter ended September 30, 2023
Revenue: $5.9 million
Result: reported results

Exact text from the filing

Collaboration revenue was $5.9 million for the third quarter of 2023, compared to $5.0 million for the same period in 2022.

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Werewolf Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001785530-23-000034

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.